13 results were returned
Medical Cannabis Network speaks with Bird & Bird’s Ben King and Sally Shorthose about the importance of product labelling and the regulation of medical cannabis.
The list of beneficiaries of transfers of value subject to compulsory disclosure in the French public “transparency” database include “persons who, in the media or on social media, present one or several health ...
Although concerned with a complex gene technology, the outcome of this appeal will have substantial impact on the validity of patents generally where doubts are raised as to the level of disclosure provided in a patent ...
The excitement around the potential for the UK cannabis market – medicinal and nutritional – to continue opening up has really intensified in the first half of 2019.
Ewan explored the legal issues which arise at various stages of the lifecycle of a medical device; from product concept, though prototyping, testing, refinement, manufacture, marketing and placing on the market.
Today in Actavis v ICOS the Supreme Court unanimously ruled that the ICOS patent for a Tadalafil dosing regime was invalid. Lord Hodge gave the only judgment, with Lady Hale, Lord Kerr, Lord Sumption and Lord Briggs in ...
A majority postulates a new "outward presentation test" to deal with the infringement of second medical use patents.
Earlier this year (17 July 2019) in Takeda UK Limited v F. Hoffmann-La Roche AG Mr Justice Colin Birss of the Patents Court of the English High Court of Justice handed down a judgment holding that Roche’s European ...
Following seminal “denigration” cases from the French, Danish and Italian competition authorities, our competition team looks into this new practice of exclusionary abuse.
In the LexisNexis case analysis, Senior IP Associate, Will Smith, talks about the decision in the following matter: Neurim Pharmaceuticals (1991) Ltd & Anor v Generics UK Ltd (t\a MYLAN)  EWHC 3270 (Pat). This ...